The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis

類似資料

• Population pharmacokinetics of darbepoetin alfa in haemodialysis and peritoneal dialysis patients after intravenous administration
  著者:: Takama, Hirotaka, 等
  出版事項: (2007)
• Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism
  著者:: Akizawa, Tadao, 等
  出版事項: (2019)
• Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
  著者:: Akizawa, Tadao, 等
  出版事項: (2018)
• Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study”
  著者:: Akizawa, Tadao, 等
  出版事項: (2019)
• A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients
  著者:: Fukagawa, Masafumi, 等
  出版事項: (2017)